Cybin (NASDAQ:HELP) Insider Purchases $1,043,100.00 in Stock

Cybin Inc. (NASDAQ:HELP) insider Paul Glavine acquired 90,000 shares of the stock in a transaction dated Monday, August 31st. The shares were purchased at an average cost of $11.59 per share, with a total value of $1,043,100.00. Following the completion of the purchase, the insider owned 4,071,252 shares of the company’s stock, valued at approximately $47,185,810.68. The trade was a 2.26% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Paul Glavine also recently made the following trade(s):

• On Tuesday, September 8th, Paul Glavine bought 100,000 shares of Cybin stock. The shares were purchased at an average price of $12.47 per share, with a total value of $1,247,000.00.
• On Thursday, September 3rd, Paul Glavine bought 100,000 shares of Cybin stock. The stock was acquired at an average cost of $11.78 per share, for a total transaction of $1,178,000.00.

Cybin Price Performance

Shares of NASDAQ:HELP opened at $12.97 on Friday. The stock’s 50-day moving average is $9.97 and its 200 day moving average is $6.89. The company has a market cap of $980.66 million, a PE ratio of -4.29 and a beta of 0.63. Cybin Inc. has a 1 year low of $3.76 and a 1 year high of $14.35.

Cybin (NASDAQ:HELP) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.11). Analysts expect that Cybin Inc. will post -2.95 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in HELP. Pale Fire Capital SE bought a new stake in shares of Cybin during the second quarter valued at approximately $1,015,000. Millennium Management LLC grew its stake in Cybin by 1,388.5% in the fourth quarter. Millennium Management LLC now owns 1,028,549 shares of the company’s stock worth $8,414,000 after purchasing an additional 959,448 shares during the period. Bank of America Corp DE raised its holdings in Cybin by 66.8% in the second quarter. Bank of America Corp DE now owns 29,443 shares of the company’s stock worth $247,000 after purchasing an additional 11,790 shares in the last quarter. Osaic Holdings Inc. lifted its position in Cybin by 46.7% during the second quarter. Osaic Holdings Inc. now owns 7,543 shares of the company’s stock valued at $63,000 after buying an additional 2,400 shares during the period. Finally, AXQ Capital LP purchased a new position in Cybin during the second quarter valued at $75,000. Institutional investors own 17.94% of the company’s stock.

Analyst Ratings Changes

HELP has been the topic of several recent analyst reports. TD Cowen lifted their price target on shares of Cybin from $8.00 to $62.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Wells Fargo & Company began coverage on shares of Cybin in a report on Monday, July 27th. They issued an “overweight” rating and a $16.00 price objective for the company. Finally, Wall Street Zen raised shares of Cybin from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 29th. Five analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $48.60.

Trending Headlines about Cybin

Here are the key news stories impacting Cybin this week:

• Positive Sentiment: Insider Paul Glavine bought 100,000 shares for approximately $1.25 million on September 8, increasing his direct ownership by 2.40%. Insider Eric H. L. So also purchased 100,000 shares for about $1.24 million, lifting his stake by 2.29%. These transactions follow additional purchases by both insiders in late August and early September, representing a notable pattern of open-market buying and likely supporting investor confidence. Eric So SEC filing Paul Glavine SEC filing
• Positive Sentiment: Cybin’s commercial operations are scheduled to receive investor exposure at the Morgan Stanley 24th Annual Global Healthcare Conference on September 16. CEO Michael Halstead is expected to participate in a fireside chat, potentially providing updates on the company’s psychedelic-based mental-health drug pipeline. Morgan Stanley conference announcement
• Neutral Sentiment: Reported short interest was zero shares with a zero-day days-to-cover ratio. However, the filing also showed an invalid “NaN” percentage change, making the data unreliable as an indicator of short-selling pressure.
• Negative Sentiment: Cybin remains an unprofitable clinical-stage biotechnology company. Its latest quarterly loss of $0.91 per share was worse than the expected $0.80 loss, and analysts project a full-year loss of approximately $2.95 per share. With no new trial result or regulatory approval reported, valuation and future financing needs remain important risks after the stock’s sharp advance.

About Cybin

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.